Skip to main content

Table 3 Correlation between D-CEUS parameters and PFS and DMFS

From: Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study

Parameter changes

< 30%

≥ 30%

P value

3-year estimate (%, 95% CI)

PFS (day 8)

 Peak intensity

90.9 (73.7–100)

44.4 (11.9–76.9)

0.021

 Area under the curve

90.0 (71.4–100)

50.0 (31.0–81.0)

0.048

 Slope of wash-in (coefficient)

90.9 (73.7–100)

44.4 (11.9–76.9)

0.021

 Wash-in perfusion index

90.9 (73.7–100)

44.4 (11.9–76.9)

0.021

DMFS (day 8)

 Peak intensity

90.9 (73.7–100)

55.6 (23.1–88.1)

0.065

 Area under the curve

90.0 (71.4–100)

60.0 (23.1–88.2)

0.119

 Slope of wash-in (coefficient)

90.9 (73.7–100)

55.6 (23.1–88.1)

0.065

 Wash-in perfusion index

90.9 (73.7–100)

55.6 (23.1–88.1)

0.065

PFS (day 15)

 Peak intensity

94.1 (82.9–100)

0.0

< 0.001

 Area under the curve

92.3 (77.8–100)

42.9 (6.2–79.6)

0.038

 Slope of wash-in (coefficient)

86.7 (69.5–100)

20.0 (0–55.1)

0.002

 Wash-in perfusion index

80.0 (59.8–100)

40.0 (0–82.9)

0.072

DMFS (day 15)

 Peak intensity

88.2 (72.9–100)

0.0

< 0.001

 Area under the curve

84.6 (65.0–100)

57.1 (20.4–93.8)

0.16

 Slope of wash-in (coefficient)

93.3 (80.8–100)

20.0 (0–55.1)

< 0.001

 Wash-in perfusion index

86.7 (69.5–100)

21.9 (0–82.9)

0.024

  1. D-CEUS dynamic contrast enhanced ultrasound, PFS progression-free survival, DMFS Distant metastasis-free survival, CI confidence interval